Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN2176-3 (Rinucumab + Aflibercept) in Neovascular AMD
NCT02418754Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2015
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of rinucumab in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Started May 2015; status: terminated.
02
Drugs
rinucumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02418754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418754.